EFTR Insider Trading
Insider Ownership Percentage: 4.70%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
eFFECTOR Therapeutics Share Price & Price History
Current Price: $0.00
Price Change: ▼ Price Decrease of -0.0004 (-66.67%)
As of 12/4/2025 12:02 PM ET
eFFECTOR Therapeutics Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 11/27/2023 | Sr One Capital Management, Llc | Major Shareholder | Sell | 24,366 | $15.25 | $371,581.50 | 72,856 |  |
eFFECTOR Therapeutics Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 5/16/2024 | Blackstone Inc. | 52,343 | $0.75M | 0.0% | -96.0% | 1.419% |  |
| 5/14/2024 | StemPoint Capital LP | 132,793 | $1.91M | 0.5% | N/A | 3.599% | |
| 5/3/2024 | Carlyle Group Inc. | 192,884 | $2.72M | 0.2% | -96.0% | 5.227% | |
| 11/13/2023 | Column Group LLC | 4,026,224 | $2.42M | 1.6% | -6.6% | 9.496% | |
| 11/2/2023 | Sonora Investment Management Group LLC | 125,000 | $75K | 0.0% | N/A | 0.295% | |
| 6/5/2023 | EP Wealth Advisors LLC | 17,607 | $1.65M | 0.0% | N/A | 0.042% | |
| 5/5/2023 | Carlyle Group Inc. | 4,822,114 | $1.69M | 0.1% | N/A | 11.373% | |
| 8/16/2022 | Callan Capital LLC | 20,000 | $28K | 0.0% | N/A | 0.048% | |
| 8/2/2022 | Resolute Financial LLC | 30,000 | $43K | 0.0% | N/A | 0.072% | |
| 8/1/2022 | Parallel Advisors LLC | 1,693,559 | $2.41M | 0.1% | +150.0% | 4.092% | |
| 4/28/2022 | Parallel Advisors LLC | 677,452 | $2.74M | 0.1% | N/A | 1.637% | |
| 2/15/2022 | SR One Capital Management LP | 6,822,114 | $56.49M | 31.9% | N/A | 16.898% | |
| 2/9/2022 | Alps Advisors Inc. | 51,942 | $0.43M | 0.0% | N/A | 0.129% | |
| 2/3/2022 | OUP Management Co. LLC | 1,025,697 | $8.49M | 3.8% | N/A | 2.541% | |
| 11/16/2021 | Verition Fund Management LLC | 24,667 | $0.35M | 0.0% | N/A | 0.061% | |
| 11/15/2021 | Abingworth LLP | 4,822,114 | $67.03M | 15.2% | N/A | 11.964% | |
| 11/15/2021 | Sectoral Asset Management Inc | 2,882,744 | $40.50M | 3.4% | N/A | 7.153% | |
Data available starting January 2016
eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.
Read More on eFFECTOR Therapeutics
Volume
329 shs
Average Volume
4,097 shs
Market Capitalization
$940.80
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.99
